In patients who had increased expression of CCR2 and CCR5 in myeloid cells after receiving combination therapy with GVAX and αPD-1, the tumor-infiltrating myeloid cells were associated with increased M2-like macrophage and M-MDSC gene signatures. The gene discussed is CCR2; the disease is neoplasm.